Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

Rhea-AI Summary

Dynavax Technologies (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and live audio webcast will follow at 4:30 p.m. ET. The company focuses on developing innovative vaccines, including its approved hepatitis B vaccine, HEPLISAV-B. Dynavax is also advancing its CpG 1018 adjuvant for various infectious diseases and collaborating on vaccines for COVID-19 and other diseases.

EMERYVILLE, Calif., Feb. 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Monday, February 28, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4678925. A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company's first commercial product, HEPLISAV-B^® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, shingles, Tdap, seasonal influenza and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-call-on-february-28-2022-301484098.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its fourth quarter and full year 2021 financial results?

Dynavax will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close.

What is the time of Dynavax's conference call on February 28, 2022?

The conference call will take place at 4:30 p.m. ET on February 28, 2022.

Where can I access the conference call for Dynavax's financial results?

The conference call can be accessed through the 'Events & Presentations' page on Dynavax's investor website.

What is Dynavax's main focus as a biopharmaceutical company?

Dynavax focuses on developing and commercializing innovative vaccines to protect against infectious diseases.

What is HEPLISAV-B?

HEPLISAV-B is Dynavax's first commercial product, an adjuvanted hepatitis B vaccine approved for adults.